Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Verified Market Research | PRODUCT CODE: 1630010

Cover Image

PUBLISHER: Verified Market Research | PRODUCT CODE: 1630010

Global Pharmaceutical Drug Delivery Market by Route of Administration, Application, Facility of Use, & Region for 2024- 2031

PUBLISHED:
PAGES: 202 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Single User License
USD 3950
Multi User License
USD 4850
Enterprise User License
USD 7550

Add to Cart

Pharmaceutical Drug Delivery Market Valuation - 2024-2031

The rising prevalence of chronic diseases such as cancer, neurological disorders, and others is surging the demand for personalized medicine and treatment, thereby creating immense opportunities for the primary drivers propelling the growth of the Pharmaceutical Drug Delivery Market. According to the analyst from Verified Market Research, the global Pharmaceutical Drug Delivery Market is estimated to reach a valuation of USD 2.745 Trillion over the forecast by subjugating the revenue of USD 1.802 Trillion valued in 2023.

Furthermore, advances in drug delivery technology have a significant impact on the dynamics of the market. Continuous advancements in nanotechnology, biomaterials, and microfabrication are transforming drug delivery methods resulting in market growth and enabling the market to grow at a CAGR of 5.4% from 2024 to 2031.

Pharmaceutical Drug Delivery Market: Definition/Overview

Pharmaceutical drug delivery involves the development and implementation of systems or methods for administering medicines in a controlled and targeted manner. The primary goal is to improve medicine therapeutic efficacy while limiting potential negative effects and enhancing patient compliance. To improve medication administration efficiency, safety, and convenience, a variety of drug delivery systems are used, including oral tablets, injections, patches, and inhalers.

Furthermore, pharmaceutical drug delivery has a wide range of applications, including providing continuous-release formulations for chronic illnesses, increasing the bioavailability of poorly soluble medications, and delivering drugs directly to specific areas inside the body, such as in targeted cancer therapy. Pharmaceutical drug delivery improves treatment outcomes by adjusting medication release and absorption, decreasing unwanted effects, and enhancing overall efficacy and patient experience in healthcare.

What are the Drivers Influencing the Growth of the Pharmaceutical Drug Delivery Market?

The rising prevalence of illnesses including diabetes, cardiovascular disease, and cancer has created a need for more effective and tailored drug delivery methods. Aging populations in industrialized countries and increased healthcare awareness in emerging nations are the main factors driving the growth of the pharmaceutical drug delivery industry.

Biologics demand specific delivery systems to assure their efficacy, opening up attractive potential for companies developing solutions for oral or targeted distribution of these complex compounds. This trend indicates the industry's dedication to addressing the unique problems of delivering biologics while improving patient outcomes. As a result, the increased emphasis on biologics for complicated diseases including cancer and autoimmune disorders is increasing the demand for innovative drug delivery systems further bolstering the market.

Furthermore, the rise of emerging economies, particularly in China and India, has a substantial impact on the pharmaceutical medication delivery market. Growing healthcare spending and demand for modern medical technologies in these developing economies have expanded the market beyond conventionally developed markets.

How will Reimbursement Issues Impact the Pharmaceutical Drug Delivery Market?

The complexity of some compounds, especially biologics, which frequently experience issues with poor solubility and stability, is a major hurdle in the Pharmaceutical Drug Delivery Market. This difficulty derives from the fact that typical drug delivery systems may not adequately handle these complex compounds, limiting their therapeutic potential. Biologics' poor solubility can impede their absorption and distribution in the body, and stability difficulties can have an impact on the drug's efficacy over time.

Reimbursement issues are a key barrier in the pharmaceutical drug delivery sector. Tise challenge is convincing insurance companies and healthcare systems to cover the costs associated with novel drug delivery technology. It has a significant impact on both patient access to innovative treatments and the general viability of these technologies in the marketplace.

Furthermore, the complexities of developing complicated drug delivery systems, particularly those intended for biologics and big molecules, provide a diverse set of challenges. One significant difficulty is the high expenses associated with scaling up the production of these intricate systems to suit the demands of a larger market. Thus, manufacturing limitations are a substantial barrier in the Pharmaceutical Drug Delivery Market.

Category-wise Acumens

How Does the Dominance of the Oral Drug Delivery Impact the Drug Delivery Market?

According to VMR analysts, the oral drug delivery segment is anticipated to dominate the Pharmaceutical Drug Delivery Market. Rising demand for unmatched convenience and patient preference it offers, coupled with its cost-effectiveness, versatility, and robust infrastructure are enhancing the manufacturing and distribution of pharmaceutical drug delivery solutions.

Oral drugs tend to be the most convenient mode of administration for patients because they require minimal assistance and allow for flexible dose schedules. Patients frequently find oral drugs easier to integrate into their everyday routines, resulting in improved adherence to prescribed regimens and propelling the demand for drug delivery in the market.

Furthermore, the dominance of oral medication delivery is largely due to its cost-effectiveness. Oral drugs are often less expensive to manufacture and distribute than alternative delivery methods, making them a more accessible and cost-effective option for both patients and healthcare providers. This cost advantage not only benefits patients by making pharmaceuticals more affordable, but it also allows for wider distribution and availability, contributing to the segment's market domination.

How Does The Prevalence Of Infectious Diseases Drive The Pharmaceutical Drug Delivery Market?

Infectious Diseases segment is estimated to hold the largest share of the Pharmaceutical Drug Delivery Market during the forecast period. The prevalence of infectious diseases increased R&D activity and government supporting the screening and discovery of biopharmaceuticals after the occurrence of the COVID-19 pandemic. The constant need to tackle the occurrence of infectious diseases is leading to the dominance of this segment in the pharmaceutical drug delivery industry.

The rise in these diseases, combined with the growing challenge of antibiotic resistance, has resulted in an urgent need for effective and targeted drug delivery methods. As a result, pharmaceutical companies are focusing their efforts on creating new methods of delivery to meet the unique needs of infectious illness treatments in the market.

Furthermore, increased government funding and regulatory actions have provided a favorable climate for the expansion of the pharmaceutical medication delivery market in infectious diseases. Collaboration between the public and private sectors has facilitated research and development activities, allowing scientific advances to be translated into practical solutions for infectious disease treatments.

Country/Region-wise Acumens

How will Demand for Pharmaceutical Drug Delivery in North America Influence the Market?

According to VMR Analysis, North America is estimated to dominate in the Pharmaceutical Drug Delivery Market during the forecast period. A high incidence of chronic illnesses is propelling the development of sophisticated healthcare infrastructure and an increase in research and development (R&D) activities in the pharmaceutical industry. Thus, the rising need to treat the prevalent diseases is leading to the dominance of North America in the Pharmaceutical Drug Delivery Market.

The region has a well-established and sophisticated healthcare system, including cutting-edge facilities and a professional workforce. Such modern infrastructure supports enhances the productivity of efficient drug delivery systems as per the patient's health, effectively fostering the growth of the Pharmaceutical Drug Delivery Market.

Furthermore, the FDA's stringent regulatory criteria have a significant impact on the pharmaceutical environment in North America. The FDA's commitment to maintaining high standards in drug research and delivery instills trust in consumers and healthcare professionals, cementing North America's reputation as a dependable and trustworthy market for pharmaceutical products.

Will Asia Pacific Prove Opportunistic for the Pharmaceutical Drug Delivery Market?

Asia Pacific is estimated to grow at the highest CAGR in the Pharmaceutical Drug Delivery Market during the forecast period. An increase in the aging population is demanding more well-equipped healthcare infrastructure with affordable treatment, thereby surging the need for pharmaceutical drug delivery solutions in the region. Also, an increase in disposable income and a higher middle class is contributing toward increased healthcare expenditure, thereby creating immense growth opportunities for the market.

Infectious diseases and respiratory problems are especially widespread in many Asian nations, demanding affordable and accessible medicinal treatments. The emphasis on cost is consistent with the region's healthcare goals, ensuring that a wider range of people may benefit from these pharmaceutical developments resulting in increased demand for drug delivery in this region.

Furthermore, emerging economies, such as China and India, are proving opportunistic for the pharmaceutical drug delivery industry. These countries are rapidly developing their pharmaceutical sectors, with expanded R&D activity, manufacturing capabilities, and relationships with global pharmaceutical companies. As these markets grow, they contribute considerably to overall regional market growth, positioning Asia-Pacific as a hub for pharmaceutical innovation and delivery system innovations.

Competitive Landscape

The competitive landscape of the pharmaceutical drug delivery industry is dynamic, with a wide range of competitors providing novel solutions. Collaborations and strategic alliances between pharmaceutical companies and drug delivery technology providers help to shape a competitive landscape characterized by continual innovation and a desire for market distinction.

Some of the prominent players operating in the global Pharmaceutical Drug Delivery Market include:

AbbVie, Johnson & Johnson, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novartis AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Catalent, Inc., Vectura Group plc, Alkermes Plc, Endo Pharmaceuticals Inc, Intract Pharma, Inc., Kaleo, Inc., Emisphere Technologies, Inc., 3M Drug Delivery Systems.

Latest Developments:

In January 2024, Vivtex, a major biopharmaceutical company, and AI Proteins, a modern AI-powered protein design platform, announced a strategic R&D collaboration to create innovative, orally delivered biologic medicines for inflammatory illnesses. This cooperation intends to use AI to produce highly targeted and effective biologics with better oral bioavailability, possibly transforming millions of people's treatment options.

In January 2024, Pfizer and Catalent collaborated to create a new oral delivery system for biologics, marking a significant advancement in overcoming the restrictions of traditional injections. This device uses Catalent's unique Zydis ODT technology to deliver biologics quickly and efficiently via the oral route.

In January 2024, Novartis collaborated with Intract Pharma to create a unique oral formulation of Parkinson's disease treatment. This partnership aims to increase patient adherence and lessen the negative effects associated with current injectable therapies.

In January 2024, 3M introduced a novel microneedle patch for pain management, which provides a non-invasive and long-lasting alternative to typical topical pain drugs. This patch delivers medication directly to the underlying tissues, providing long-lasting pain relief for up to 12 hours.

Pharmaceutical Drug Delivery Market, By Category

  • Route of Administration:
  • Oral Drug Delivery
  • Injectable Drug Delivery
  • Topical Drug Delivery
  • Ocular Drug Delivery
  • Pulmonary Drug Delivery
  • Implantable Drug Delivery
  • Transmucosal Drug Delivery
  • Nasal Drug Delivery
  • Application:
  • Infectious Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory Diseases
  • Central Nervous System Disorders
  • Autoimmune Diseases
  • Other Applications
  • Facility of Use:
  • Hospitals
  • Ambulatory Surgery Centers
  • Home Care Settings
  • Diagnostic Centers
  • Other Facilities of Use
  • Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Product Code: 7648

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET

  • 1.1 OVERVIEW OF THE MARKET
  • 1.2 SCOPE OF REPORT
  • 1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 DATA MINING
  • 3.2 VALIDATION
  • 3.3 PRIMARY INTERVIEWS
  • 3.4 LIST OF DATA SOURCES

4 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET OUTLOOK

  • 4.1 OVERVIEW
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
    • 4.2.2 RESTRAINTS
    • 4.2.3 OPPORTUNITIES
  • 4.3 PORTERS FIVE FORCE MODEL
  • 4.4 VALUE CHAIN ANALYSIS

5 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 OVERVIEW
  • 5.2 Oral Drug Delivery
  • 5.3 Injectable Drug Delivery
  • 5.4 Topical Drug Delivery
  • 5.5 Ocular Drug Delivery
  • 5.6 Pulmonary Drug Delivery
  • 5.7 Implantable Drug Delivery
  • 5.8 Transmucosal Drug Delivery
  • 5.9 Nasal Drug Delivery

6 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

  • 6.1 OVERVIEW
  • 6.2 INFECTIOUS DISEASES
  • 6.3 CANCER
  • 6.4 CARDIOVASCULAR DISEASES
  • 6.5 DIABETES
  • 6.6 RESPIRATORY DISEASES
  • 6.7 CENTRAL NERVOUS SYSTEM DISORDERS
  • 6.8 AUTOIMMUNE DISEASES
  • 6.9 OTHER APPLICATIONS

7 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.3 AMBULATORY SURGERY CENTERS
  • 7.4 HOME CARE SETTINGS
  • 7.5 DIAGNOSTIC CENTERS
  • 7.6 OTHER FACILITIES OF USE

8 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 8.1 OVERVIEW
  • 8.2 NORTH AMERICA
    • 8.2.1 U.S.
    • 8.2.2 CANADA
    • 8.2.3 MEXICO
  • 8.3 EUROPE
    • 8.3.1 GERMANY
    • 8.3.2 U.K.
    • 8.3.3 FRANCE
    • 8.3.4 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 CHINA
    • 8.4.2 JAPAN
    • 8.4.3 INDIA
    • 8.4.4 REST OF ASIA PACIFIC
  • 8.5 REST OF THE WORLD
    • 8.5.1 LATIN AMERICA
    • 8.5.2 MIDDLE EAST AND AFRICA

9 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPANY MARKET RANKING
  • 9.3 KEY DEVELOPMENT STRATEGIES

10 COMPANY PROFILES

  • 10.1 JOHNSON & JOHNSON
    • 10.1.1 OVERVIEW
    • 10.1.2 FINANCIAL PERFORMANCE
    • 10.1.3 PRODUCT OUTLOOK
    • 10.1.4 KEY DEVELOPMENTS
  • 10.2 NOVARTIS INTERNATIONAL AG
    • 10.2.1 OVERVIEW
    • 10.2.2 FINANCIAL PERFORMANCE
    • 10.2.3 PRODUCT OUTLOOK
    • 10.2.4 KEY DEVELOPMENTS
  • 10.3 F. HOFFMANN-LA ROCHE AG
    • 10.3.1 OVERVIEW
    • 10.3.2 FINANCIAL PERFORMANCE
    • 10.3.3 PRODUCT OUTLOOK
    • 10.3.4 KEY DEVELOPMENTS
  • 10.4 PFIZER INC.
    • 10.4.1 OVERVIEW
    • 10.4.2 FINANCIAL PERFORMANCE
    • 10.4.3 PRODUCT OUTLOOK
    • 10.4.4 KEY DEVELOPMENTS
  • 10.5 BAYER AG
    • 10.5.1 OVERVIEW
    • 10.5.2 FINANCIAL PERFORMANCE
    • 10.5.3 PRODUCT OUTLOOK
    • 10.5.4 KEY DEVELOPMENTS
  • 10.6 BOEHRINGER INGELHEIM
    • 10.6.1 OVERVIEW
    • 10.6.2 FINANCIAL PERFORMANCE
    • 10.6.3 PRODUCT OUTLOOK
    • 10.6.4 KEY DEVELOPMENTS
  • 10.7 MERCK & CO., INC.
    • 10.7.1 OVERVIEW
    • 10.7.2 FINANCIAL PERFORMANCE
    • 10.7.3 PRODUCT OUTLOOK
    • 10.7.4 KEY DEVELOPMENTS
  • 10.8 SANOFI
    • 10.8.1 OVERVIEW
    • 10.8.2 FINANCIAL PERFORMANCE
    • 10.8.3 PRODUCT OUTLOOK
    • 10.8.4 KEY DEVELOPMENTS
  • 10.9 GLAXOSMITHKLINE PLC
    • 10.9.1 OVERVIEW
    • 10.9.2 FINANCIAL PERFORMANCE
    • 10.9.3 PRODUCT OUTLOOK
    • 10.9.4 KEY DEVELOPMENTS
  • 10.10 ABBVIE INC.
    • 10.10.1 OVERVIEW
    • 10.10.2 FINANCIAL PERFORMANCE
    • 10.10.3 PRODUCT OUTLOOK
    • 10.10.4 KEY DEVELOPMENTS

11 APPENDIX

    • 11.1.1 RELATED RESEARCH
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!